About This BPC-157 TB-500 Reading Room
A two-band reading of the published Wolverine-blend literature and the FDA access record — sourced, cold, and unaffiliated with any clinic or seller.
What this site is
Rx Wolverine reads the peer-reviewed research on the BPC-157 TB-500 blend and its two constituents, alongside the FDA record, and sets it down plainly — every quantitative claim cited to its source. The work is a reading of published science.
No clinic stands behind it and no clinician is on staff; it offers no medical guidance; it makes, sells, and distributes nothing; and it names no pharmacies, vendors, or telehealth providers. The site exists to make the existing literature legible — what was measured, in which species, by which route — and to surface the regulatory and access status of these compounds accurately.
Why "Rx" is editorial framing, not a service
The "rx" in this domain is editorial framing — a position this publisher occupies relative to the literature and the access question, not a claim about services offered here. We do not write prescriptions, fill them, evaluate patients, or facilitate access to any substance. When this site discusses compounding, 503A categories, or the FDA review calendar, it is describing the regulatory landscape as a matter of general information, not advising any reader on obtaining anything.
The distinction matters most on a topic like this one. The BPC-157 TB-500 blend is two unapproved peptides that FDA once placed in Category 2 and now lists as withdrawn nominations, with no word from the agency on what that allows a compounder to do. A digest's job is to report that status honestly — the present-tense facts, cited to FDA, and the open questions left open — not to route anyone around it.
How we handle the evidence
Three editorial commitments shape every page. First, we separate the constituents: BPC-157's evidence and TB-500's evidence are presented as the distinct bodies of work they are, never blended into a single overstated claim. Second, we mark the gaps before the findings — the absence of any controlled combination study, the thin human data, the fragment-versus-full-length Thymosin Beta-4 identity caveat — because the absence is the most important fact about this blend [10], [4]. Third, we cite. Every dose figure, percentage, half-life, and regulatory date maps to a numbered source in the references.
This is a literature digest, assembled for general readers. It is not a course of treatment, not a recommendation, and not an endorsement of the compound or the blend.